Who to call at KYNTRA BIO, INC., and when
Fundz watches for the moments KYNTRA BIO, INC. starts buying, and tells you who to reach.
- An alert the day KYNTRA BIO, INC. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at KYNTRA BIO, INC., from your own LinkedIn network
KYNTRA BIO, INC.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
kyntrabio.comAI Executive Summary
AI-powered analysis of 8-K filing content
Kyntra Bio appointed Andrew E. Singer, an investment banking executive with biopharma expertise, as a Class III director and Audit Committee member effective October 1, 2026. This board expansion strengthens governance and strategic guidance for the company's oncology and rare disease focus.
Key Takeaways
Andrew E. Singer appointed as Class III director with term expiring in 2029, bringing investment banking and biopharma strategic expertise
Singer joins the Audit Committee, enhancing financial oversight and governance capabilities
2 more takeaways
Related Filings (1)
1 more filing from KYNTRA BIO, INC. in the last 90 days
Filing Overview
What This Means
KYNTRA BIO, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.